Stock Analysis
Regeneron Pharmaceuticals IncREGN
P/E 18.81×· 5Y range 7.68–32.06×· 64th percentile of history
Sector: Healthcare · Industry: Biotechnology
AnalystsBuy38 analystsP/E 18.8× sits at the 64th percentile of its 5.086926762491444-year history.
Cash covers 433% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Financial Health100
- Profitability69
Risks
- Growth25
Mixed picture — no clear quality or value edge.
Bull Case
- ✓Altman Z 7.8 — safe-zone balance sheet
- ✓Interest coverage 46.7× — debt well covered
What's happening with REGN
Profile
Strong financial health and moat; growth and valuation lag behind.
How is each axis scored?
- Valuation41/100 · Weak
- P/E vs own history (64th pct)5/25
- FCF yield (4.6%)12/25
- P/S (5.2x)12/25
- EV/EBIT (19.5x)12/25
- Growth25/100 · Weak
- Revenue CAGR (-2.8%)0/25
- Net income CAGR (-13.6%)0/25
- EPS CAGR 5Y (-12.9%)0/25
- Fwd implied growth (40.7%)25/25
- Profitability69/100 · Moderate
- ROIC (12.3%)12/25
- ROE (13.8%)12/25
- Net margin (27.9%)25/25
- Operating margin (24.7%)20/25
- Financial Health100/100 · Strong
- Altman Z (7.83)25/25
- Current ratio (4.13)25/25
- Interest coverage (46.7x)25/25
- Net cash / debt (Net cash)25/25
- Quality69/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.50)20/25
- FCF conversion (87%)22/25
- Margin stability (σ 9.2%)12/25
- Moat100/100 · Strong
- ROIC >12% years (9/10 yrs)25/25
- Median gross margin (86.7%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 18.4%)25/25
Risk Flags
- ⚠SBC 6.4% of revenue — real dilution cost
- ⚠Revenue shrinking 2.8%/yr
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. Show more
The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Headquarters: TARRYTOWN, NY · Employees: 15,410 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
41D+P/E (TTM)18.8xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 7.7x–32.1x · 64th pct
P/FCF23.0xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.3%–12.1% · 36th pct
P/S (TTM)5.25xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.8x–10.3x · 34th pct
EV/EBIT19.5xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 6.4x–33.5x · 63rd pct
EV/Sales5.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E13.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.61xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.04B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.46%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio8.7%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
69BROIC12.3%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE13.8%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA10.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin27.9%A
Grade A: HighNet Income / Revenue
Operating Margin24.7%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin84.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin24.2%A
Grade A: HighFCF / Revenue
True FCF Margin17.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR-2.8%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-13.6%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-12.9%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth40.7%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-7.0%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income22.8%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue6.4%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score7.83A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.13xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.78xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage46.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.06xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt4.33xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
69BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.50A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion86.9%A
Grade A: StrongFCF / Net Income
Margin Stability9.2%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue5.9%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.38xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -50 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -463 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -380 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -454 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -38 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -66 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -376 | |
MURPHY ANDREW J Filed | MURPHY ANDREW J | SellOpen market sale | -121 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
100A+ROIC >12% Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)86.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor18.4%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$42.04
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$77.32
Cash & short-term investments per share (Finnhub)
Book Value / Share$306.69
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.99B
Total debt obligations (short + long term)
Cash & Equiv.$8.61B
Cash and short-term investments
Net Debt$-6.62BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$31.26B
Shareholders' equity (book value)
Asset / Liability4.36xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$81.54B
Current Market Capitalization
Beta0.14B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Regeneron Pharmaceuticals Inc (REGN)
REGN is down 0.70% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Regeneron Pharmaceuticals Inc. Altman Z-Score of 7.83 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.50 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -3%), which weighs on the growth outlook.
- Regeneron Pharmaceuticals Inc converts about 24% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
See how REGN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all REGN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | After-hours | 782.54 | +3.91% | 2.40 |
| Sep 28 | Regular | 755.30 | -4.15% | -2.51 |
Frequently Asked Questions about REGN
What is the current Regeneron Pharmaceuticals Inc (REGN) stock price?
REGN is trading at $790.74 at the last market close, down 0.70% on the session. PreMarketPrice tracks REGN pre-market, intraday and after-hours prices.
Is REGN stock a buy right now?
PreMarketPrice's quantitative model rates Regeneron Pharmaceuticals Inc's financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is REGN stock overvalued?
Regeneron Pharmaceuticals Inc trades at a trailing P/E of 18.8 and our valuation score rates it 41/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Regeneron Pharmaceuticals Inc report earnings?
No confirmed earnings date is currently scheduled for REGN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Regeneron Pharmaceuticals Inc operate in?
Regeneron Pharmaceuticals Inc operates in the Healthcare sector, within the Biotechnology industry. The Related Stocks section lists sector peers for comparison.
What does Regeneron Pharmaceuticals Inc do?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.
About Regeneron Pharmaceuticals Inc (REGN) Stock
Regeneron Pharmaceuticals Inc (REGN) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry. As of the latest update, Regeneron Pharmaceuticals Inc is trading at $790.74, down 0.70% on the day with a market capitalization of $81.5 billion. The financial health score for REGN is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for REGN stock.
REGN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Regeneron Pharmaceuticals Inc (REGN) across multiple dimensions:
- Pre-market price & movement: Real-time REGN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for REGN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Regeneron Pharmaceuticals Inc across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for REGN.
- Sector peers: Compare REGN against 6 other healthcare stocks on key financial metrics.
Is REGN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Regeneron Pharmaceuticals Inc (REGN) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Regeneron Pharmaceuticals Inc (REGN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.